0001144204-17-051541.txt : 20171005
0001144204-17-051541.hdr.sgml : 20171005
20171005172635
ACCESSION NUMBER: 0001144204-17-051541
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170901
FILED AS OF DATE: 20171005
DATE AS OF CHANGE: 20171005
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dusseux Eric Michel
CENTRAL INDEX KEY: 0001713593
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-54717
FILM NUMBER: 171125329
MAIL ADDRESS:
STREET 1: 1 RUE DU CAPOT
CITY: CALUIRE-ET-CUIRE
STATE: I0
ZIP: 69300
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Bionik Laboratories Corp.
CENTRAL INDEX KEY: 0001508381
STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
IRS NUMBER: 271340346
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 483 BAY STREET
STREET 2: N105
CITY: TORONTO
STATE: A6
ZIP: M5G2C9
BUSINESS PHONE: 1.416.640.7887
MAIL ADDRESS:
STREET 1: 483 BAY STREET
STREET 2: N105
CITY: TORONTO
STATE: A6
ZIP: M5G2C9
FORMER COMPANY:
FORMER CONFORMED NAME: Drywave Technologies, Inc.
DATE OF NAME CHANGE: 20130814
FORMER COMPANY:
FORMER CONFORMED NAME: Strategic Dental Management Corp.
DATE OF NAME CHANGE: 20101220
4/A
1
v476557_4a.xml
OWNERSHIP DOCUMENT
X0306
4/A
2017-09-01
2017-09-15
0
0001508381
Bionik Laboratories Corp.
BNKL
0001713593
Dusseux Eric Michel
C/O BIONIK LABORATORIES CORP.
483 BAY STREET, N105
TORONTO
A6
M5G2C9
ONTARIO, CANADA
1
1
0
0
Chief Executive Officer
Employee Stock Option (Right to Buy)
0.161
2017-09-01
4
A
0
6122677
0
A
2027-09-01
Common Stock, par value $0.001
6122677
6122677
D
This amendment to the Statement of Change in Beneficial Ownership on Form 4, originally filed with the Securities and Exchange Commission on September 15, 2017, is being filed to correct an administrative error concerning the number of shares of stock options granted to the reporting person.
One-sixth of the option will be vested and exercisable as of the September 1, 2017 date of grant, and the unvested portion of the option will become vested and exercisable as follows: (a) 50% in 5 equal annual installments on each of the five anniversaries of the date of the issuance of the option; and (b) 50% in 5 equal separate tranches annually based on Dr. Dusseux's achievement of annual performance goals to be established by the Board in consultation with Dr. Dusseux.
The extent to which each separate tranche becomes vested shall be determined by reference to Dr. Dusseux's annual performance as measured by reference to the performance targets set for that performance period. In the event a specific tranche is not fully vested, that tranche shall not be forfeited, but shall remain outstanding, and may become vested as a result of Dr. Dusseux's future performance at an above target level or as a result of accelerated vesting on the occurrence of any other event that triggers accelerated vesting.
/s/ Eric Michel Dusseux
2017-10-05